Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories
Obesity drugs, pipeline investment, and manufacturing capacity are reshaping the pharmaceutical industry's growth equation.
Amgen Inc (AMGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 1,589,554 | $575,609,596 | +1% | 0.17% |
| 2. | D E Shaw D. E. Shaw | 1,290,217 | $467,213,380 | +625% | 0.22% |
| 3. | 918,100 | $332,462,372 | +24% | 0.04% | |
| 4. | 847,300 | $306,824,276 | +38% | 0.04% | |
| 5. | Citadel Investment Group Ken Griffin | 703,984 | $254,926,687 | +281% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.50 | 10 | $1,655.00 | 3,582 | 2015-08-19 | Filing | |
| $166.64 | 3,000 | $499,907.10 | 3,572 | 2015-08-19 | Filing | |
| $152.29 | 1,500 | $228,435.00 | 2,000 | 2015-02-05 | Filing | |
| $152.29 | 1,500 | $228,435.00 | 2,000 | 2015-02-05 | Filing | |
| $111.77 | 894 | $99,919.25 | 185,013 | 2014-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $416.43 | 1,252 | $521,364.85 | 6,404 | 2026-08-13 | Filing | |
| $412.57 | 2,000 | $825,134.00 | 6,404 | 2026-08-11 | Filing | |
| $402.54 | 1,821 | $733,033.35 | 12,462 | 2026-08-06 | Filing | |
| $402.54 | 2,069 | $832,864.36 | 12,462 | 2026-08-06 | Filing | |
| $402.16 | 1,000 | $402,160.10 | 7,340 | 2026-08-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,706 | $7,041,746 | 0.66% | |
| 2. | 15,821 | $6,668,844 | 0.49% | |
| 3. | 4,450 | $1,875,829 | 0.41% | |
| 4. | 2,263 | $953,877 | 0.08% | |
| 5. | 2,032 | $856,768 | 0.26% |
News See All
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease.
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing...
Why Amgen’s Pipeline Just Got More Interesting
Amgen Inc. (NASDAQ:AMGN)'s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease.
Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back
Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago. Amgen is not leaving.
A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc.
SCHD vs. VIG: Which Dividend ETF Has the Edge in 2026?
The Schwab U.S. Dividend Equity ETF (SCHD) and the Vanguard Dividend Appreciation ETF (VIG) are two popular dividend ETFs, but they are built for d...
Amgen (AMGN) Fell 5% on a Drug That Isn't Even Its Own. Here's the Lp(a) Bet Now in Question.
Amgen Inc. (NASDAQ:AMGN) shed roughly $12 billion in market value after hours on September 4, 2026. The stock declined by about 5% to $415.
Novartis' Failed Cholesterol Drug Trial Sends Ionis and Amgen Tumbling
Few concepts in cardiovascular medicine have sparked as much optimism as Lp(a)-lowering medications.
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc.
Hedge Fund Resource Center